FAQ: How the Shift to PMOS Reshapes Women's Supplement Innovation

A major shift in the nomenclature of one of the most prevalent endocrine and metabolic disorders is officially underway. Following a multi-year global consensus process, the condition traditionally known as polycystic ovary syndrome (PCOS) has been renamed polyendocrine metabolic ovarian syndrome (PMOS).

The decision, published in The Lancet and supported by a coalition of 56 international organizations, aims to address long-standing inaccuracies that have historically hindered clinical diagnosis, research funding, and patient care.¹ For brands monitoring the women's wellness sector, this FAQ breaks down what this landmark change means for patients, practitioners, and the broader industry.

Why Was the Name Changed From PCOS to PMOS?

The previous name focused on only one organ, mistakenly implying an increase in abnormal or pathological ovarian cysts, which are not actually a feature of the condition. Instead, as Dr. Thais Aliabadi, OBGYN explains in an interview with Nutritional Outlook, what appears on an ultrasound are small, immature follicles that reflect disrupted ovulation and altered hormone signaling.²

By narrowing clinical attention to a single organ and reproductive symptoms alone, the old name frequently obscured the broader metabolic and endocrine complexities of the disorder. This misalignment contributed to significant knowledge gaps, widespread diagnostic delays, fragmented care, and patient stigma. The update helps move clinical medicine away from reducing the condition to an isolated ultrasound finding and toward understanding a whole-body hormonal picture. “My hope is that this name change helps women feel seen,” states Dr. Aliabadi. “That we move away from reducing this condition to an ultrasound finding and toward understanding the whole-body hormonal and metabolic picture.”

What Does the New Name Stand For?

The name PMOS was selected to align terminology with the underlying multisystem pathophysiology of the disorder, which affects approximately 170 million women worldwide. The updated breakdown includes:

• Polyendocrine: Formalizes the understanding that the condition is a whole-body hormonal picture underpinning multiple interacting hormone systems—such as elevated androgen levels (like testosterone)—rather than being an isolated ovarian issue.
• Metabolic: Leads with and formally recognizes fundamental metabolic features, notably insulin resistance and elevated long-term risks for diabetes and cardiovascular disease.
• Ovarian: Retains the crucial connection to reproductive health, recognizing that disrupted ovulation, cycle irregularities, and fertility challenges remain defining clinical features.

What Are the Underlying Metabolic Mechanisms?

The core biology of PMOS is an intricate conversation between hormones and metabolism, Dr. Aliabadi explains. A primary driver under the surface is insulin resistance, which occurs when the body must produce increasingly higher levels of insulin to move glucose from the bloodstream into cells for energy. These elevated insulin levels subsequently stimulate the ovaries to produce more androgens.

This resulting hormonal fluctuation can trigger an array of diverse symptoms, spanning reproductive endpoints, dermatological conditions (such as acne, excess facial or body hair growth, and scalp hair thinning), weight management difficulties, sleep issues, and psychological or mental health effects like anxiety or brain fog.

“The way we name things and conditions in medicine drives what happens to those patients and outcomes,” explains Sameena Rahman, MD, a board-certified OB/GYN, in an interview with Nutritional Outlook.³ “It drives research, it drives who takes care of that patient and in which silo in medicine is responsible for that disease. Really changing it to metabolic, understanding that this is a multi-system disease—it shifts our understanding in not only the condition, but how we treat it and who should treat it.”

What Does This Mean for the Nutraceutical and Wellness Industry?

For manufacturers and product developers in the health and dietary supplement spaces, the transition to PMOS signals a broadening of relevant market categories. While previous product formulation heavily targeted a narrow focus on fertility or cycle regulation, the new nomenclature validates a more holistic approach.

PMOS formally emphasizes systemic elements like insulin resistance and inflammation. Ingredients drawing attention in previous PCOS research include traditional botanicals like shatavari—noted for its hormonal adaptogen properties that help normalize dysregulated signaling and ovarian function—as well as foundational nutrients such as folic acid, coenzyme Q10 (CoQ10), and omega-3 fatty acids.

Targeted supplementation can play a significant supporting role as part of a broader treatment plan, Dr. Aliabadi explains. “For many women with PMOS, the goal is to improve insulin sensitivity, stabilize blood sugar, reduce inflammation, support ovulation, improve energy, and protect long-term cardiovascular and metabolic health. That often means prioritizing protein, fiber, strength training, regular movement, sleep, stress reduction, and reducing dramatic blood sugar spikes.”

How Long Will the Transition Take?

Rebranding the condition creates a strategic transition window for updated clinical messaging, updated lifestyle-oriented solutions, and ongoing patient education. The collaborative effort focused heavily on maximizing scientific accuracy and clarity while eliminating patient stigma. It incorporated iterative global surveys involving over 14,300 respondents, including individuals with lived experience and multidisciplinary health professionals from all world regions.

Transition to the new name will occur over a three-year period and the shift aims to reframe healthcare conversations, recognizing and treating the condition as a complex, lifelong multi-system disease.

For more on the science, innovations, and leaders driving progress in the women's health category, dive into a New Vision for Women's Health: Trends and Innovation That Push the Category Forward, a spotlight on the research and product development in women’s health.

This article was created with assistance from AI. The content has been reviewed and edited by Erin McEvoy, Associate Editor. For more information on the extent and nature of AI usage, please contact us.

References

1. McEvoy E. Global Consensus Renames PCOS to Polyendocrine Metabolic Ovarian Syndrome (PMOS). May 13, 2026. Accessed May 29, 2026. https://www.nutritionaloutlook.com/view/global-consensus-renames-pcos-to-polyendocrine-metabolic-ovarian-syndrome-pmos-
2. Aliabadi T, McEvoy E. PCOS to PMOS: Why the Name Change Reflects Metabolism. Nutritional Outlook. May 28, 2026. Accessed May 29, 2026. https://www.nutritionaloutlook.com/view/pcos-pmos-why-name-reflects-metabolism
3. Rahman S. Krawiec S, Saraceno N. Why Renaming PCOS to PMOS Could Reshape Women's Health Care and Research. May 28, 2026. May 29, 2026. https://www.nutritionaloutlook.com/view/why-renaming-pcos-to-pmos-could-reshape-women-s-health-care-and-research